



Regeneron Announces Upcoming Investor Conference Presentation

August 24, 2018

TARRYTOWN, N.Y., Aug. 24, 2018 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast its management presentation at the Morgan Stanley 16th Annual Global Healthcare Conference at 9:55 a.m. Eastern Time on Wednesday, September 12, 2018.

The session may be accessed from the "Investors & Media" page of Regeneron's website at <http://investor.regeneron.com/events.cfm>. A replay of the webcast will be archived on the Company's website and will be available for 30 days.

About Regeneron Pharmaceuticals, Inc.

Regeneron (NASDAQ: REGN) is a leading biotechnology company that invents life-transforming medicines for people with serious diseases. Founded and led for 30 years by physician-scientists, our unique ability to repeatedly and consistently translate science into medicine has led to six FDA-approved treatments and numerous product candidates in development, all of which were homegrown in our laboratories. Our medicines and pipeline are designed to help patients with eye disease, heart disease, allergic and inflammatory diseases, pain, cancer, infectious diseases and rare diseases.

Regeneron is accelerating and improving the traditional drug development process through our proprietary *VelociSuite*[®] technologies, such as *VelocImmune*[®] which produces optimized fully-human antibodies, and ambitious research initiatives such as the Regeneron Genetics Center, which is conducting one of the largest genetics sequencing efforts in the world.

For additional information about the company, please visit www.regeneron.com or follow @Regeneron on Twitter.

Contact Information:

Investor Relations

Manisha Narasimhan, Ph.D.

914.847.5126

manisha.narasimhan@regeneron.com

Corporate Communications

Hala Mirza

914.847.3422

hala.mirza@regeneron.com

 View original content: <http://www.prnewswire.com/news-releases/regeneron-announces-upcoming-investor-conference-presentation-300701709.html>

SOURCE Regeneron Pharmaceuticals, Inc.

News Provided by Acquire Media